Trial Profile
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethasone followed by maintenance in primary refractory or relapsed bortezomib naive multiple myeloma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms REMMYDYS
- 02 Jul 2011 New trial record